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This review focuses on new findings in the field of epidemiology, asthma and rhinitis, clinical allergy and allergens in 2018. It complements the first year in review which focuses on 
experimental models of allergic disease, basic mechanisms and clinical mechanisms in 2018. 
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In this article, we describe developments in the field of clinical allergy as described by 
Clinical and Experimental Allergy in 2018; epidemiology, asthma and rhinitis, clinical 
allergy and allergens are all covered.
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1  | EPIDEMIOLOGY
In 2018, several highly interesting publications in the area of clin-
ical and respiratory epidemiology have been published in Clinical 
and Experimental Allergy. Many papers have focused on pregnancy 
and early life risk factors for subsequent asthma, eczema and food 
allergies. Although few of those may change clinical practice per se, 
they will hopefully be combined with other available papers to cre-
ate evidence-based guidelines with advice to pregnant couples and 
parents. Other publications have focused on phenotype definitions, 
time trends and interactions of genes and the environment.
1.1 | Antenatal exposures
The association between exposures preconception or during preg-
nancy and subsequent asthma or allergic disease is of great inter-
est, and this year has seen several papers in the area.1 As such, 
Korhonen et al2 showed that exposure to serologically confirmed 
acute enterovirus during pregnancy was inversely associated with 
atopic outcome in the offspring; this was not the case for acute 
influenza A or Mycoplasma pneumonia. Preconception use of ma-
ternal folic acid supplement and higher vitamin B12 concentrations 
at birth was reported to affect childhood lung function depending 
on MTHFR-C677T carriership.3 There is also a growing interest in 
the association between grandparental exposure and asthma or al-
lergic disease in the grandchild. Lodge et al4 studied the link be-
tween grandmaternal smoking during pregnancy and grandchild 
use of asthma medications in a Swedish register-based study and 
found that children aged 1-6 years had an increased asthma risk 
if their grandmothers had smoked during pregnancy, independent 
of maternal smoking. This finding may support possible epigenetic 
transmission of risk from environmental exposures in previous gen-
erations. Finally, birth order has previously been shown to have 
an effect on the allergic disease.5 Nevertheless, there is a need to 
carefully interpret potential causal effects and to take genetic and 
environmental confounding as well as residual confounding into ac-
count.6,7 Consequently, systematic reviews and meta-analysis are 
very powerful and Flanigan's elegant review on prenatal maternal 
psychosocial stress and offspring's asthma and allergic disease in 
this year's Clinical and Experimental Allergy addressed causality 
very well.8 Findings that atopic diseases and depression or anxiety 
tend to occur together in families indicate a genetic explanation for 
comorbidity, although this was not supported in a large twin study 
by Brew et al.9
There may also be factors that modify the association between a 
risk factor and subsequent asthma or allergic disease. Reports from 
Isle of Wight have suggested that breastfeeding duration may mod-
ify the effect of smoking during pregnancy on eczema from early 
childhood to adolescence,10 and in a Finnish birth cohort, the as-
sociation between pet exposure and sensitization was modified by 
pollen exposure in early pregnancy.11
1.2 | Big data
The definition, prevalence and time trends of outcomes such as 
asthma and allergic disease from early childhood to adolescence are 
also of great interest. Analysing “big data” allows data-driven meth-
ods such as hierarchical clustering and principal component analysis, 
which can be used to identify useful outcomes. Deliu et al12 have 
used this approach to identify asthma subtypes that may further the 
understanding of asthma heterogeneity, exacerbations and severity. 
Time trends of food allergy from infancy to adolescence as well as 
transition of allergic sensitizations to common allergens as a prog-
nostic factor for eczema, asthma and rhinitis are reported from the 
Isle of Wight cohort.13,14
1.3 | Postnatal exposures
Environmental exposure post-pregnancy has also been surveyed in 
Clinical and Experimental Allergy. Caillaud et al15 report short-term 
effect of outdoor mould spore exposure on prescribed allergy medi-
cation sales in Central France. Quite unexpectedly, Brough et al16 
found that higher levels of environmental exposure to peanut in the 
first few months of life appeared to increase the probability of devel-
oping school-age peanut sensitization in atopic children.
Finally, Clinical and Experimental Allergy has also included re-
ports on dietary pattern and respiratory pattern from nine European 
countries,17 the influence of maternal and child's country of birth on 
the prevalence of parent-reported asthma, eczema and a diagnosis 
of anaphylaxis in Australia18 and new interacting genes in eczema.19
2  | CLINIC AL ALLERGY
2.1 | Component resolved diagnosis
We are increasingly using components to manage clinical allergy. 
Blankestijn et al20 looked at whether Ara h 7 is useful in diagnosing 
peanut allergy. They compare it to Ara h 2 and Ara h 6 isoforms. 
Ara h 7, Ara h 2 and Ara h 6 had comparable utilities for diagnosing 
peanut allergy. Most individuals were co-sensitized to all three 2S 
albumins Ara h 2, 6 or 7 but some were only sensitized to one leading 
to the possibility of misdiagnosis when only one 2S albumin is used 
in a diagnostic algorithm.
Continuing on this theme, Geiselhart et al21 had looked at 
whether component resolved diagnosis can help with buckwheat 
allergy. They identified a number of immunoreactive proteins from 
the crude buckwheat extract: Fag e 1 (legumin), Fag e 2 (2S albumin), 
Fag e 4 (hevein-like antimicrobial peptides) and Fag e 5 (vicilin-like). 
All four components showed better diagnostic precision than the ex-
tract-based ImmunoCAP.
Finally, Uotila et al22 examined the IgE sensitization profiles in 
patient with different clinical responses to peanut and tree nuts in 
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a birch pollen area using the ISAC system. Specific IgE to Ara h 2 
and Ara h 6 discriminated peanut allergic and tolerant participants. 
Only a minority of participants had species-specific sensitizations to 
tree nuts suggesting that many could potentially introduce them into 
their diet.23
2.2 | Chronic spontaneous urticaria
Chronic urticaria is a problematical condition for patients. Jörg et 
al24 conducted a double-blind, randomized, placebo-controlled 
trial to assess the mode of action of omalizumab in these patients. 
Omalizumab therapy led to a significant reduction in FcεRI receptor 
density on basophils within a week persisting after the last injection. 
This contrasted with a lack of change in basophil activation testing 
suggesting that omalizumab's affect is cellular.
Continuing on the urticarial theme, Ruft et al25 have developed 
and validated a disease-specific quality of life questionnaire for 
cholinergic urticaria (CholU-QoL). Such questionnaire is helpful to 
quantify condition specific issues for patients and may be helpful for 
clinical trials and improving routine patient management.
2.3 | Atopic dermatitis
Fieten et al26 assessed whether the claim that Alpine climate therapy 
reduces the severity of atopic dermatitis. Using a pragmatic, open, 
randomized, controlled trial design, they enrolled children with dif-
ficult to treat atopic dermatitis. The interventions were 6-week per-
sonalized integrative multidisciplinary treatment period in the alpine 
climate or in moderate maritime climate. For up to 6 weeks after the 
Alpine intervention, atopic dermatitis was found to be better but this 
benefit was not maintained.
Another approach to allergen avoidance is the temperature-con-
trolled laminar airflow device. Gore et al27 have assessed it efficacy 
in severe atopic eczema in an open label, proof of concept study. 
Participants saw a clinically meaningful reduction in severity and an 
increase in quality of life over the 6-month intervention.
Continuing on the atopic dermatitis theme, a systematic review 
and a meta-analysis by Waidyatillake et al28 suggested that the age 
of solid food introduction is not associated with the development of 
eczema.
2.4 | Food allergy
In the last year, we have seen evidence of the potentially severity 
of food allergy.29,30 Many papers in 2018 focused on improving the 
management of food allergy.
Avoiding triggering allergens is the major challenge for pa-
tients with food allergy. Begen et al31 looked at whether the 2014 
European allergen information legislation had changed how consum-
ers with food allergy behaved when eating out. Using both in-depth 
interviews and surveys with consumers with food allergy, they found 
a generally positive response with better availability of information 
and awareness of food allergy in eating out venues. The authors did 
though highlight continued inconsistencies in the implementation of 
the legislation.
Reier-Nilsen et al32 assessed whether clinical or immunologi-
cal factors are associated with the threshold for reactivity at dou-
ble-blind, placebo-controlled food challenge in children with peanut 
allergy. They found that basophil activation, peanut skin prick test 
diameter and the ratio of peanut-specific IgE/total IgE were signifi-
cantly associated with the threshold of reactivity and lowest ob-
served adverse events level. Unfortunately, none of the factors were 
associated with severity. So we still lack predictive markers for the 
severity of allergic reactions.
Appel et al33-35 looked for ways to improve the diagnostic ap-
proach for sesame allergy. Neither skin prick testing with commer-
cial extracts nor basophil activation testing was perfect diagnostic 
tools but the authors suggested that they made be useful in parallel.
Lastly, the BSACI published guidance for the prevention of food 
allergy in children in 2018.36 The guidance complemented the report 
from the UK's Scientific Advisory Committee on Nutrition (SACN) 
and the Committee on Toxicity of Chemicals in Food, Consumer 
Products and the Environment (COT). In summary, it recommended 
exclusive breastfeeding until around 6 months of life and introduc-
tion of age appropriate complementary foods from around 6 months 
of age alongside continued breastfeeding. However, the BSACI also 
recommended that where an infant was at higher risk of developing 
food allergy, parents may wish to start complementary foods (in-
cluding egg and peanut) from 4 months of age in an age-appropriate 
manner to avoid risk of choking.
There is a constant effort to improve the effectiveness of oral 
immunotherapy for foods. Fauquert et al37 tried to use peanut in 
sealed capsules to bypass the upper gastrointestinal tract ant poten-
tially minimize adverse effects. In a randomized, double-blind and 
placebo-controlled trial design, they found similar mild oropharyn-
geal adverse effects in both arms but more frequent digestive and 
systematic adverse events in the peanut arm, so probably not a de-
sirable approach.
2.5 | Drug allergy
Cabañas et al38 looked at the value of the lymphocyte transforma-
tion test in drug reaction with eosinophilia and systemic symptoms 
(DRESS). In the recovery phase of DRESS, the lymphocyte transfor-
mation test had a sensitivity of 73% and specificity of 82%. This was 
much better than in the acute phase. This may be a helpful approach 
especially given that these patients cannot be challenged with the 
likely trigger(s).
Last year saw the publication of the Royal College of Anaesthetists 
6th National Audit Project.39,40 They describe the causes and inves-
tigation of peroperative anaphylaxis using a registry approach. The 
authors noted that harmonization of the approach to testing, access 
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to services, and MHRA reporting was needed. They noted that dy-
namic tryptase evaluation should be adopted with standardized 
clinic reports containing appropriate details of tests, conclusions, 
avoidance, cross-reactivity and suitable alternatives.
2.6 | Support groups
There is a limit to the support available from healthcare profession-
als. Jones et al41 explored what motivates young people with aller-
gies to engage with support groups using in-depth, semi-structured 
interviews. They reported very positive findings with reported im-
proved self-esteem and confidence and improved adherence to self-
management behaviours. We need to better signpost our patients to 
these support groups.
2.7 | Allergy in the elderly
Finally, Gray et al42 published a case series of older people referred 
to an allergy clinic. While allergy was excluded in many cases, a num-
ber of new allergies were diagnosed leading to important changes in 
management. This is an overlooked population for allergist.
3  | A STHMA AND RHINITIS
3.1 | Inducible laryngeal obstruction
In 2018, Lee et al43 revisited the difficult associations and differ-
ences between vocal cord dysfunction (perhaps better called induc-
ible laryngeal obstruction) and asthma in 69 consecutive patients 
attending a “difficult asthma service” that focuses on complex co-
morbidities. Their main objective was to compare a questionnaire 
approach to diagnosis of vocal cord dysfunction with direct vocal 
cord visualization during a mannitol challenge. In a detailed analysis, 
the authors confirm the frequent coexistence of asthma and cord 
dysfunction (~40%) and the inability to diagnose the condition with 
questionnaires.
3.2 | Asthma and pregnancy
It was always taught that asthma in pregnancy could be considered 
in thirds—a third remain unchanged, a third deteriorate and a third 
improve, which seems to be born out in observational studies.44 
Further, pre-pregnancy severity predicts pregnancy exacerba-
tions.45 In a study from Ali et al46 take a further step and show that 
for mothers whose asthma is stable at enrolment and who have no 
history of severe exacerbations or current controller therapy are 
extremely unlikely to have an exacerbation during pregnancy and 
may therefore not require asthma surveillance.
3.3 | Triggers of asthma attacks
Looi et al47 have thrown some light on why Rhinovirus (RV) infections 
might lead to more severe asthma. They examined the effects of RV 
on tight junction-associated proteins on airway epithelial cells (AEC) 
from asthmatic and non-asthmatic children. The AECs of children 
with asthma showed upregulation of mRNA for tight junction pro-
teins but lower levels of these proteins compared to non-asthmatics. 
Infection of the cells with RV showed reductions in these proteins 
in all children though the effect was prolonged in asthmatic AECs. 
In addition, epithelial resistance was lower in asthmatic children and 
decreased further following RV infection. Thus, tight junction and 
epithelial dysfunction amplified by RV may be one mechanism by 
which RV infection induces asthma.
Personal air pollution monitoring is still in its infancy but likely 
set to move into the mainstream with improved response times and 
precision and provide new insights into associations with respiratory 
disease. Additionally, such monitoring can now be linked to wearable 
applications that document physical activity, respiratory rate and a 
host of physiological data. In a small study of patients with asthma, 
personal air pollution exposure did not seem to be associated with 
asthma control or lung function.48
3.4 | Underlying pathophysiology
A study by Periyalil et al49 looks at pro- (M1) and anti-inflammatory 
macrophages (M2) in visceral and subcutaneous fat in obese asth-
matic and non-asthmatic subjects undergoing bariatric surgery. The 
key findings relate to the increased M1 macrophages in visceral fat in 
obese asthmatics compared to non-asthmatics and a higher ratio of 
M1 to M2 in more severe asthma with positive correlations between 
macrophage types, lung function and markers of systemic inflamma-
tion. The study suggests at least one cellular component that might 
link obesity, inflammation and asthma that are clearly worthy of fur-
ther study.
Meanwhile, Hastie et al50 somewhat boldly attempted to try to 
disentangle a wide range of sputum cytokines and chemokines in 
relation to asthma severity. Additionally, they looked at the asthma 
severity and the various cytokines using factor analysis. The factor 
analysis was able to identify ten factors that grouped at least two cy-
tokines per group and two groups that contained at least 16 common 
cytokines. But strikingly there were multiple overlapping inflam-
matory pathways identified across the whole spectrum of asthma 
severity suggesting that at the level of inflammatory proteins, the 
picture is complex, and therefore, specific cytokine biomarkers or 
even interventions targeting specific cytokines are unlikely to be 
successful in severe asthma.
The Mogensen et al51 used 3 years of NHANES data to tease out 
the combined and separate elevated type 2 asthma markers, FeNO 
and blood eosinophils with asthma outcomes. When both markers 
were elevated, lung function was reduced and more severe asthma 
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reported. Elevated blood eosinophils alone were associated with 
more exacerbations and exacerbations of greater severity. The most 
important corollary of these findings would seem to be that across a 
broad spectrum of asthma severity both biomarkers are required to 
define current and future outcomes.
In a small group of preschool children, with severe recurrent 
wheezing who were bronchoscoped, Lezmi et al52 evaluated the 
early airway pathology in relation to school-age asthma severity. 
Not surprisingly most children went on to have persistent asthma 
in later childhood and the severity and frequency of exacerbations 
correlated positively with submucosal eosinophil counts and lung 
function correlated positively with neutrophil counts, possibly re-
lated to ICS treatment. As in many studies, the more eosinophils the 
worse the asthma.
The Pentraxin family of ancient, conserved soluble proteins 
which include CRP, play an important role in recognizing foreign and 
altered self antigens. In a study by Gao et al,53 members of the fam-
ily were measured as potential markers of eosinophilic and non-eo-
sinophilic asthma. Of the various pentraxins measured, pentraxin 
3 in sputum showed the best predictive value for non-eosinophilic 
asthma with an AUC of 0.78.
3.5 | Phenotype specific therapy
In an open study of inhaled corticosteroid (ICS) withdrawal amongst 
36 non-eosinophilic adult asthmatics, two thirds were able to stop 
ICS or reduce the dose.54 In those who were able to stop, asthma 
control significantly improved following cessation. Predictors of fail-
ure were age and a higher eosinophil count, suggesting that perhaps 
those unable to stop or reduce in fact had an important eosinophilic 
component masked by their ICS. The study suggests that true non-
eosinophilic asthma does not benefit from ICS.
3.6 | Impact of asthma
Hiles et al published a useful, if small, web-based database of adults 
with severe asthma.55 Poorer asthma control generally was associ-
ated with absenteeism and self-reported impairment at work, while 
severe asthma per se at baseline was only associated with impair-
ment at work. An important message here is that when exploring 
workplace issues associated with asthma, absenteeism alone is a 
poor measure and details of workplace engagement are as important 
as absenteeism in determining the effect of more severe asthma.
3.7 | Predicting future asthma attacks
Trying to predict future asthma exacerbations amongst severe 
asthmatics has been of obvious research interest. In a study by 
Kimura et al,56 an adult cohort of severe asthmatics was reviewed 
regularly over 3 years. FeNO was the single most useful predictor 
of exacerbations after controlling for prior history of exacerbations, 
this being an obviously strong predictor of future exacerbations. 
The subjects in this study were generally good medication compliers 
with 30% on systemic corticosteroids. The report is interim as the 
authors plan to study the cohort for a further 3 years.
H2S has recently been shown to be an important gaseous sig-
nalling molecule involved in modulating airway and vascular smooth 
muscle. In this study of asthmatics of varying severity, healthy sub-
jects' serum and sputum H2S have been examined.
57 Serum levels 
were lower and sputum levels higher in those with frequent exac-
erbations compared to those with fewer and elevated sputum H2S 
predicted future exacerbations. Thus, a higher ratio of sputum to 
serum H2S seems to predict more exacerbations though it is entirely 
unclear why H2S should behave in this way.
3.8 | Long-term outcomes of asthma
In a study by Blackman et al,58 49 of 100 children hospitalized with 
severe wheezing before 24 months were followed up in early adult-
hood. When compared to controls, all were more likely to report 
current asthma. Those with RV or respiratory syncytial virus (RSV) 
were more likely have larger responses to bronchodilators but no 
significant differences in baseline lung function. Interestingly, RV 
early wheezers had higher FeNO than controls or RSV wheezers 
suggesting a stronger association between RV and subsequent al-
lergic asthma.
3.9 | Asthma and food allergy
In this study by Patelis et al,59 sensitization to food allergens amongst 
asthmatic adults was associated with higher levels of type 2 mark-
ers (FeNO, ECP, periostin and urinary eosinophil-derived neurotoxin) 
than asthmatics sensitized to aeroallergens only. Specific food sen-
sitizations were associated with specific patterns of elevated type 2 
markers especially periostin suggesting perhaps that food allergen 
sensitivity is more strongly associated with systemic type 2 inflam-
mation than previously suggested. Of interest would be the associa-
tions in those with food allergy and in children with food sensitivities.
There is an interrelationship between asthma and food allergy 
which Bonner et al60 describe. Many patients have both. Allergies to 
foods have been associated with severe asthma exacerbations while 




A number of authors have identified new, clinically relevant aller-
gens. Ruethers et al61 have demonstrate that parvalbumin is the 
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major fish allergen in Asia-Pacific fish species and found a novel al-
lergen called Ras k 1 in Indian mackerel.
Soongrung et al62 have worked on the house dust mite species 
Blomia tropicalis, an important cause of allergic diseases in tropical 
and subtropical regions. They identified Blo t 7 as an important 
B tropicalis allergen that stimulates the TLR2 signalling pathways in 
AEC.
Novel allergens have also been identified for orange,63 donkey's 
milk64 and soya65 in 2018.
4.2 | Variation in allergens
Dölle et al66 looked at celery stalks and celeriac roots. They found 
that different cultivars of celery had different levels of the major al-
lergen Api g 1. This is likely to explain the different allergenicity of 
different cultivars.
4.3 | Linking structure to allergenicity
Prodic et al67 examined the stability of peanut allergens in the stom-
ach. Ara h 2 and Ara h 6 remained mostly intact. This would preserve 
their allergenic capacity explaining their role in allergic reactions to 
peanuts. Hayen et al68 have also looked at these two peanut aller-
gens assessing the allergenicity of different isoforms.
Continuing with nut allergens, Blankestijn et al69 looked at 
whether sensitization to Jug r 4 might explain why Jug r 1, 2 and 3 
do not explain all cases of walnut allergy. Although the walnut 11S 
globulin Jug r 4 turned out to be a minor allergen, it had a very high 
positive predictive value for walnut allergy.
For food allergen components, we know that there is usually a 
relationship between the component to which an individual is sensi-
tized and the presenting clinical symptoms. Park et al70 looked to see 
whether there is a similar relationship with the Dermatophagoides fa-
rina allergens. Participants with rhinitis and/or asthma were mainly 
sensitized to the major allergens Der f 1 and Der f 2, whereas those 
with atopic dermatitis were sensitized to these major components 
plus one or more minor allergen component (eg, Der f 11, Der f 13, 
Der f 14, Der f 32 and Der f Alt a 10). This begs the chick or egg ques-
tion: does this difference in sensitization patterns drive the different 
expressions of different allergic diseases or are the different allergic 
diseases responsible for the development of different sensitization 
patterns?
Allergen sensitizations does not always have a clinical signifi-
cance. Stoevesandt et al71 look at the sensitization profile of 490 
dermatology patients without a history of sting-induced anaphylac-
tic reactions. Many had sensitization to each of the wasp and bee 
components despite having no clinical history of a reaction.
Cross-reactivity is an important concept for allergens. Cantillo 
et al72 have looked at cross-reactivity between tropomyosins in 
mosquito and house dust mite at humoral and cellular levels. They 
found both humoral and cellular cross-reactivity improving our un-
derstanding of these allergens.
4.4 | The matrix
We know that the allergen matrix can have an important impact on 
allergenicity. Pettersson et al73 looked at whether a high or low fat 
content food matrix would affect allergic reactions to peanut. The 
high-fat recipe was associated with significantly worse reactions al-
though the eliciting dose was similar.
5  | CONCLUSIONS
The year 2018 provided further advances in the field of allergy.74 We 
look forward to publishing more interesting observations in 2020.
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